In recent decades, with the significant progress in understanding the inherent immune biology related to cancer, effective immunotherapy treatments for cancer have gradually emerged (Fyfe et al., 1995; Atkins et al., 1999; Kantoff et al., 2010) and reached an important turnover in the history of cancer treatment as named by Science magazine the “breakthrough of 2013” due to the striking proof-of-concept data of immune checkpoint anti-CTLA-4 and PD-1 antibodies as well as CAR therapy (Couzin-Frankel, 2013). Here, CTLA4 is linked to cancer.